The stock of Akero Therapeutics Inc. (NASDAQ:AKRO) decreased by -$1.75 on Wednesday to $49.59, down -3.41 percent. The last five days have seen an average of 1,524,563 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$5.24. The average number of shares traded over the last 20 days was 971,991, while the average volume over the last 50 days totaled 694,506.
AKRO stock appreciated 3.31% since last month. On 08/25/23, the company’s shares reached a one-month low of $45.87. The stock touched a high of $58.38 on 06/13/23, after rallying from a low of $25.21 in 52 weeks. The price of AKRO stock has declined by -9.51% or -$5.24 this year, reaching a new high 3 times. Still, the stock price is down -15.06% from the 52-week high.
Insider Transactions
AKRO stock investors should be aware that Akero Therapeutics Inc. (AKRO) stock had its last reported insider trading activity 1 day ago on Sep 19. On Sep 19, Director Graham G. Walmsley acquired 400,000 shares at $26.00 each. This transaction resulted in the insider spending $10,400,000. On Sep 01, Cheng Andrew sold 25,000 shares at a price of US$49.77. After the transaction, the insider now owns 462,680 shares. Chief Development Officer Yale Catriona had earlier sold 5,745 shares on Aug 28 for $49.99 a share. The transaction was completed for $287,191.
Financial Health
For the three months ended June 29, Akero Therapeutics Inc.’s quick ratio was 29.80, while its current ratio was 29.80, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.04, and the total debt to equity ratio is 0.04.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AKRO’s return on assets (ROA) during the last 12 months has been -26.40%. In the meantime, the return on equity (ROE) for the last 12 months was -29.00%.
Earnings Surprise
According to Akero Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Akero Therapeutics Inc.’s quarterly earnings would be -$0.6, but it ended up being -$0.63, beating the consensus by 4.80%. At the end of Akero Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 47.37 million, while its total debt was $25.93 million. Equity owned by shareholders amounts to $55.6 million.
Technical Picture
Here’s a quick look at Akero Therapeutics Inc.’s (AKRO) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 47.28%, suggesting the stock is Neutral, with a 32.07% historical volatility rate.
The stochastic %K and %D were 54.69% and 65.73% respectively, while the average true range (ATR) was 2.06. Based on the 14-day stochastic reading of 29.92%, the RSI (14) reading is 52.33%. On the 9-day MACD Oscillator, the stock is at 0.58, and the 14-day reading is at 0.80.
Analyst Ratings
In its analyst report released on September 19, 2023, Cantor Fitzgerald began covering Akero Therapeutics Inc. (NASDAQ: AKRO). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Akero Therapeutics Inc. (AKRO) an Buy rating. AKRO is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 9 others recommend it as a buy.
What is AKRO’s price target for the next 12 months?
The current consensus forecast for the stock is between $59.00 and $83.00, with a median target price of $68.00. In analyzing these forecasts, the average price target given by analysts for Akero Therapeutics Inc. (AKRO) is $67.67.
